CA4P Is Well Tolerated, May Benefit Platinum-resistant Ovarian Cancer Patients, Trial Shows

CA4P Is Well Tolerated, May Benefit Platinum-resistant Ovarian Cancer Patients, Trial Shows
Data from the second interim analysis of the ongoing Phase 2/3 FOCUS study has shown that Mateon Therapeutics’ CA4P (combretastatin a4-phosphate), also known as fosbretabulin, may prolong the time to disease progression or death, when added to the standard of care for platinum-resistant ovarian cancer. “We are encouraged that early data on the primary endpoint of

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *